Drug-induced kidney disease (DIKD) is a common, often preventable cause of acute kidney injury, making it a critical area of focus for pharmacists. A pharmacist’s vigilance in screening for high-risk medications, understanding the mechanisms of nephrotoxicity, and implementing preventative strategies is paramount to patient safety. As detailed in the Patient Care 4 curriculum, managing DIKD is a key competency. This quiz will test your knowledge on the mechanisms of nephrotoxicity for various drug classes and the management strategies used to mitigate harm.
1. NSAIDs can cause a hemodynamically-mediated acute kidney injury (AKI) by what mechanism?
- a. Vasodilation of the efferent arteriole.
- b. Direct toxicity to the tubular cells.
- c. Inhibiting prostaglandins, leading to vasoconstriction of the afferent arteriole.
- d. Causing an allergic reaction in the interstitium.
Answer: c. Inhibiting prostaglandins, leading to vasoconstriction of the afferent arteriole.
2. ACE inhibitors and ARBs can contribute to AKI by:
- a. Causing vasoconstriction of the afferent arteriole.
- b. Causing vasodilation of the efferent arteriole, which decreases glomerular pressure.
- c. Forming crystals in the renal tubules.
- d. Inducing an allergic reaction.
Answer: b. Causing vasodilation of the efferent arteriole, which decreases glomerular pressure.
3. Aminoglycosides, such as gentamicin, are well-known to cause which type of intrinsic kidney injury?
- a. Acute Interstitial Nephritis (AIN)
- b. Glomerulonephritis
- c. Acute Tubular Necrosis (ATN)
- d. Vasculitis
Answer: c. Acute Tubular Necrosis (ATN)
4. A patient develops a fever, rash, and eosinophilia one week after starting a new penicillin antibiotic. This clinical picture is most suggestive of:
- a. Prerenal AKI
- b. Postrenal AKI
- c. Drug-induced Acute Interstitial Nephritis (AIN)
- d. Acute Tubular Necrosis (ATN)
Answer: c. Drug-induced Acute Interstitial Nephritis (AIN)
5. High doses of intravenous acyclovir can cause kidney injury through which mechanism?
- a. Hemodynamic changes
- b. Allergic reaction
- c. Direct tubular toxicity
- d. Precipitation of crystals in the renal tubules (crystal nephropathy).
Answer: d. Precipitation of crystals in the renal tubules (crystal nephropathy).
6. The “Management of Drug-Induced Kidney Disease” is a specific learning module in which course?
- a. PHA5784C Patient Care 4
- b. PHA5104 Sterile Compounding
- c. PHA5703 Pharmacy Law and Ethics
- d. PHA5878C Patient Care 3
Answer: a. PHA5784C Patient Care 4
7. Which of the following is a primary strategy for preventing contrast-induced nephropathy in at-risk patients?
- a. Administering an NSAID before the procedure.
- b. Withholding all fluids 12 hours before the procedure.
- c. Intravenous hydration with isotonic saline before and after the contrast load.
- d. Administering a loop diuretic immediately after the contrast.
Answer: c. Intravenous hydration with isotonic saline before and after the contrast load.
8. The combination of which two antibiotics is associated with a higher risk of nephrotoxicity than either agent alone?
- a. Amoxicillin and azithromycin
- b. Vancomycin and piperacillin-tazobactam
- c. Ciprofloxacin and metronidazole
- d. Doxycycline and ceftriaxone
Answer: b. Vancomycin and piperacillin-tazobactam
9. The nephrotoxicity of amphotericin B is related to:
- a. Its ability to cause afferent arteriole vasoconstriction.
- b. Its ability to cause direct tubular cell damage by binding to ergosterol-like structures.
- c. Both a and b.
- d. Neither a nor b.
Answer: c. Both a and b.
10. What is the most important first step in managing any type of drug-induced kidney disease?
- a. Starting a diuretic.
- b. Discontinuing the offending agent, if possible.
- c. Obtaining a renal biopsy.
- d. Increasing the dose of the drug.
Answer: b. Discontinuing the offending agent, if possible.
11. The renal system module in Patient Care 4 covers DIKD.
- a. True
- b. False
Answer: a. True
12. A patient taking an ACE inhibitor, an NSAID, and a diuretic concurrently is at high risk for AKI. This combination is sometimes referred to as the:
- a. “Triple Threat”
- b. “Perfect Storm”
- c. “Triple Whammy”
- d. “Cardiac Cocktail”
Answer: c. “Triple Whammy”
13. A key risk factor for developing aminoglycoside-induced nephrotoxicity is:
- a. Low trough concentrations.
- b. High trough concentrations and prolonged duration of therapy.
- c. A single large dose.
- d. Administering the drug orally.
Answer: b. High trough concentrations and prolonged duration of therapy.
14. Which of the following is NOT a risk factor for developing DIKD?
- a. Pre-existing Chronic Kidney Disease (CKD)
- b. Young age
- c. Dehydration
- d. Advanced age
Answer: b. Young age
15. Calcineurin inhibitors like tacrolimus and cyclosporine can cause AKI by:
- a. Causing vasodilation of the afferent arteriole.
- b. Causing vasoconstriction of the afferent arteriole.
- c. Causing an allergic reaction.
- d. Blocking tubular secretion.
Answer: b. Causing vasoconstriction of the afferent arteriole.
16. The management of AKI is a specific topic within the Patient Care 4 curriculum.
- a. True
- b. False
Answer: a. True
17. How can the risk of crystal nephropathy from drugs like high-dose IV acyclovir or methotrexate be minimized?
- a. By restricting fluids.
- b. By administering the drug as a rapid IV bolus.
- c. By ensuring adequate hydration and sometimes alkalinizing the urine.
- d. By co-administering an NSAID.
Answer: c. By ensuring adequate hydration and sometimes alkalinizing the urine.
18. A pharmacist’s role in preventing DIKD involves:
- a. Identifying high-risk patients.
- b. Screening medication profiles for nephrotoxic drugs and combinations.
- c. Recommending appropriate monitoring of renal function.
- d. All of the above.
Answer: d. All of the above.
19. Which of the following is a platinum-based chemotherapy agent known for its significant nephrotoxicity?
- a. 5-Fluorouracil
- b. Doxorubicin
- c. Vincristine
- d. Cisplatin
Answer: d. Cisplatin
20. An active learning session on drug-induced kidney disease is part of the Patient Care 4 course.
- a. True
- b. False
Answer: a. True
21. A patient develops AKI while on a stable dose of lisinopril. The most likely scenario is:
- a. The lisinopril is the sole cause of the AKI.
- b. The patient likely developed a prerenal state (e.g., dehydration) which was exacerbated by the lisinopril.
- c. The lisinopril dose is too low.
- d. The patient has developed an allergy to lisinopril.
Answer: b. The patient likely developed a prerenal state (e.g., dehydration) which was exacerbated by the lisinopril.
22. Which of the following drug classes is a well-known cause of Acute Interstitial Nephritis (AIN)?
- a. Proton Pump Inhibitors (PPIs)
- b. Statins
- c. Metformin
- d. Calcium channel blockers
Answer: a. Proton Pump Inhibitors (PPIs)
23. The nephrotoxicity from amphotericin B is often associated with which electrolyte abnormalities?
- a. Hyperkalemia and Hypermagnesemia
- b. Hypokalemia and Hypomagnesemia
- c. Hypernatremia
- d. Hyperphosphatemia
Answer: b. Hypokalemia and Hypomagnesemia
24. An active learning session on the renal system is part of which course?
- a. PHA5784C Patient Care 4
- b. PHA5163L Professional Skills Lab 3
- c. PHA5781 Patient Care I
- d. PHA5782C Patient Care 2
Answer: a. PHA5784C Patient Care 4
25. A patient with a history of CKD needs pain control. Which of the following is the safest option from a renal perspective?
- a. Ibuprofen
- b. Naproxen
- c. Celecoxib
- d. Acetaminophen
Answer: d. Acetaminophen
26. The term “nephrotoxic” means:
- a. Healthy for the kidneys.
- b. Cleared by the kidneys.
- c. Poisonous or damaging to the kidneys.
- d. A type of diuretic.
Answer: c. Poisonous or damaging to the kidneys.
27. Which of the following is NOT a characteristic of drug-induced AIN?
- a. It is dose-dependent.
- b. It is an idiosyncratic hypersensitivity reaction.
- c. It can present with fever and rash.
- d. It can be caused by beta-lactam antibiotics.
Answer: a. It is dose-dependent.
28. The principles of renal clearance and dosing are covered in the Drug Therapy Individualization course.
- a. True
- b. False
Answer: a. True
29. To prevent cisplatin-induced nephrotoxicity, a key intervention is:
- a. Aggressive IV hydration with chloride-containing fluids and sometimes mannitol.
- b. Administering an ACE inhibitor concurrently.
- c. A low-sodium diet.
- d. A potassium supplement.
Answer: a. Aggressive IV hydration with chloride-containing fluids and sometimes mannitol.
30. The “Management of DIKD” is a lecture within the Renal System module.
- a. True
- b. False
Answer: a. True
31. Once-daily dosing of aminoglycosides is thought to be less nephrotoxic than traditional (multiple daily dose) dosing because:
- a. It results in lower peak concentrations.
- b. The prolonged drug-free period allows for recovery of the tubular cells.
- c. It is not less nephrotoxic.
- d. It uses a lower total daily dose.
Answer: b. The prolonged drug-free period allows for recovery of the tubular cells.
32. A patient taking which sulfa-containing drug may develop crystal nephropathy if they are not well-hydrated?
- a. Furosemide
- b. Sulfamethoxazole
- c. Glipizide
- d. Hydrochlorothiazide
Answer: b. Sulfamethoxazole
33. What is the best way a pharmacist can prevent DIKD?
- a. By recommending the lowest possible dose of every drug.
- b. By reviewing a patient’s medication profile for nephrotoxic agents and assessing their individual risk.
- c. By never dispensing an NSAID.
- d. By telling patients to drink 4 liters of water a day.
Answer: b. By reviewing a patient’s medication profile for nephrotoxic agents and assessing their individual risk.
34. The combination of an ACE inhibitor and an ARB is recommended to maximize renal protection.
- a. True
- b. False
Answer: b. False
35. A patient on vancomycin develops a rising serum creatinine. This is likely due to which mechanism?
- a. Prerenal azotemia
- b. Direct tubular toxicity (ATN)
- c. Allergic interstitial nephritis (AIN)
- d. Both b and c are possible.
Answer: d. Both b and c are possible.
36. Monitoring _____ is key to preventing toxicity with aminoglycosides and vancomycin.
- a. peak concentrations
- b. random concentrations
- c. trough concentrations and AUC
- d. BUN only
Answer: c. trough concentrations and AUC
37. Which of the following statements about DIKD is true?
- a. It is always irreversible.
- b. It is often reversible if the offending drug is discontinued promptly.
- c. It only occurs in elderly patients.
- d. It is not a common problem.
Answer: b. It is often reversible if the offending drug is discontinued promptly.
38. The pharmacology of antimicrobials known to be nephrotoxic is covered in the Patient Care 2 course.
- a. True
- b. False
Answer: a. True
39. A patient’s SCr increases from 0.8 to 1.1 mg/dL after starting an ARB. What is the appropriate action?
- a. Stop the ARB immediately.
- b. Continue the ARB and recheck labs in 1-2 weeks, as this is likely an expected hemodynamic effect.
- c. Double the ARB dose.
- d. Add an ACE inhibitor.
Answer: b. Continue the ARB and recheck labs in 1-2 weeks, as this is likely an expected hemodynamic effect.
40. An active learning session on DIKD is part of which course?
- a. PHA5784C Patient Care 4
- b. PHA5163L Professional Skills Lab 3
- c. PHA5781 Patient Care I
- d. PHA5782C Patient Care 2
Answer: a. PHA5784C Patient Care 4
41. The primary mechanism of lithium-induced kidney disease is:
- a. Acute tubular necrosis.
- b. Causing nephrogenic diabetes insipidus and chronic tubulointerstitial disease.
- c. Allergic interstitial nephritis.
- d. Crystal nephropathy.
Answer: b. Causing nephrogenic diabetes insipidus and chronic tubulointerstitial disease.
42. Which class of drugs should be used cautiously with calcineurin inhibitors due to an increased risk of nephrotoxicity?
- a. Statins
- b. NSAIDs
- c. Beta-blockers
- d. PPIs
Answer: b. NSAIDs
43. A pharmacist’s role in medication safety includes identifying patients with which risk factors for DIKD?
- a. Dehydration
- b. Pre-existing CKD
- c. Concurrent use of multiple nephrotoxins
- d. All of the above
Answer: d. All of the above.
44. If a patient must receive a known nephrotoxin, the pharmacist should recommend:
- a. Using the highest possible dose.
- b. Using the lowest effective dose for the shortest possible duration.
- c. Not monitoring renal function to avoid finding problems.
- d. Combining it with another nephrotoxin.
Answer: b. Using the lowest effective dose for the shortest possible duration.
45. Which of the following is NOT a mechanism of drug-induced kidney disease?
- a. Direct tubular toxicity
- b. Glomerular disease
- c. Increased renal perfusion
- d. Obstructive nephropathy
Answer: c. Increased renal perfusion
46. The management of DIKD is primarily:
- a. Aggressive treatment with diuretics and steroids.
- b. Supportive care and removal of the offending agent.
- c. Initiation of dialysis in all cases.
- d. A 14-day course of antibiotics.
Answer: b. Supportive care and removal of the offending agent.
47. A “drug-induced” disease is also known as a(n) _____ disease.
- a. idiopathic
- b. iatrogenic
- c. infectious
- d. congenital
Answer: b. iatrogenic
48. An active learning session on drug-induced kidney disease is part of which course module?
- a. Module 7: Renal System
- b. Module 1: PUD and GERD
- c. Module 4: Gastrointestinal Infections
- d. Module 5: Nutrition & Weight Management
Answer: a. Module 7: Renal System
49. Preventing DIKD is a key component of:
- a. Antimicrobial stewardship
- b. Medication safety programs
- c. A pharmacist’s clinical responsibilities
- d. All of the above
Answer: d. All of the above
50. The ultimate goal of understanding DIKD is to:
- a. Be able to blame all kidney problems on medications.
- b. Minimize patient harm by preventing and managing kidney injury caused by medications.
- c. Memorize a long list of nephrotoxic drugs.
- d. Avoid dispensing any potentially nephrotoxic drug.
Answer: b. Minimize patient harm by preventing and managing kidney injury caused by medications.
